Pirtobrutinib
Bruton'S Tyrosine Kinase (Btk) Inhibitors
Sold as Jaypirca
- Drug class
- Bruton'S Tyrosine Kinase (Btk) Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 5
Overview
Pirtobrutinib is an active pharmaceutical ingredient in the Bruton'S Tyrosine Kinase (Btk) Inhibitors group (L01EL). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 1, 2026 |
| EU European Union | EMA | 1 | January 28, 2026 |
| CA Canada | Health Canada | 2 | December 23, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in • adult patients with treatment naïve CLL; • adult patients with relapsed or refractory CLL who have previously not received a BTK inhibitor; • adult patients with relapsed or refractory CLL who have previously been treated with a BTK inhibitor.
How to take
EUEuropean Union· EMA
1 product
Uses
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor.
3
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Sources & citations
- [1]MHRA (UK) · PL148950354 · revised May 1, 2026
- [2]European Medicines Agency · EMEA/H/C/005863 · revised January 28, 2026
- [3]Health Canada (DPD) · 02562006 · revised December 23, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.